Pre-Made Mirococept biosimilar, Recombinant Protein targeting C3b/C4b: Recombinant therapeutic protein for drug discovery and mechanism of action (MOA) research

Pre-Made Mirococept biosimilar, Recombinant Protein targeting C3b/C4b: Recombinant therapeutic protein is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Mirococept (APT070) is a highly effective complement inhibitor which is derived from human CR1 (CD35). It consists of three functional units: the terminal three domains of CR1 which contain its biological activities, a membrane-associating peptide and a membrane-inserting myristoyl group. The last two units permit the binding to and insertion into the cell membrane. Mirococept is unique in that it is engineered to bind to cell surfaces in bulk and can block the complement system at the C3 level. It does not inhibit proteases generally, and its action is restricted to the complement system.

Mirococept (APT070) is a recombinant complement inhibitor derived from human complement receptor type 1 (CR1, CD35). This complement inhibitory domains of CR1 (in APT070) contain C3b-binding sites that lead to dissociation and inactivation of C3b from the classical and alternative pathway convertases. Mirococept effectively blocks and reduces the generation of the activated form of C3, and thwarts the release of both C3a and C5a.